Category Press Releases

Poxel

Poxel Reports Positive Preclinical Results for PXL065 in HCM

Poxel Reports Positive Preclinical Results for PXL065 in HCM POXEL SA, a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for chronic and serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, has announced positive…

Read MorePoxel Reports Positive Preclinical Results for PXL065 in HCM
Drug Resistance

Kairos Pharma Publishes Breakthrough on Overcoming Drug Resistance in NSCLC

Kairos Pharma Publishes Breakthrough on Overcoming Drug Resistance in NSCLC Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, has announced a significant breakthrough in addressing drug resistance to EGFR-targeted therapies for non-small cell lung cancer (NSCLC). A recent peer-reviewed publication in…

Read MoreKairos Pharma Publishes Breakthrough on Overcoming Drug Resistance in NSCLC
Psoriasis

InnoCare Doses First Patient in Phase III Trial of ICP-488 for Psoriasis in China

InnoCare Doses First Patient in Phase III Trial of ICP-488 for Psoriasis in China InnoCare Pharma, a leading biopharmaceutical company dedicated to developing innovative treatments for cancer and autoimmune diseases, has announced a significant milestone in its clinical development efforts.…

Read MoreInnoCare Doses First Patient in Phase III Trial of ICP-488 for Psoriasis in China
Scholar Rock, Conference

Scholar Rock Unveils Phase 3 SAPPHIRE Data at 2025 MDA Conference

Scholar Rock Presents Comprehensive Phase 3 SAPPHIRE Trial Data at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference Scholar Rock, a late-stage biopharmaceutical company committed to advancing groundbreaking treatments for neuromuscular diseases, cardiometabolic disorders, and other serious conditions influenced…

Read MoreScholar Rock Unveils Phase 3 SAPPHIRE Data at 2025 MDA Conference